PT - JOURNAL ARTICLE AU - Lapierre, Simon Grandjean AU - Bedwani, Stéphane AU - DeBlois, François AU - Fortin, Audray AU - Cuervo, Natalia Zamorano AU - Zerouali, Karim AU - Caron, Elise AU - Potvin, Philippe Morency AU - Gagnon, Simon AU - Nguissan, Nakome AU - Arlotto, Pascale AU - Hardy, Isabelle AU - Boutin, Catherine-Audrey AU - Tremblay, Cécile AU - Coutlée, François AU - Guise, Jacques de AU - Grandvaux, Nathalie TI - Clinical Evaluation of In House Produced 3D Printed Nasopharyngeal Swabs for COVID-19 Testing AID - 10.1101/2021.05.26.21257548 DP - 2021 Jan 01 TA - medRxiv PG - 2021.05.26.21257548 4099 - http://medrxiv.org/content/early/2021/06/03/2021.05.26.21257548.short 4100 - http://medrxiv.org/content/early/2021/06/03/2021.05.26.21257548.full AB - 3D printed alternatives to standard flocked swabs were rapidly developed to provide a response to the unprecedented and sudden need for an exponentially growing amounts of diagnostic tools to fight the pandemics of COVID-19. In light of the anticipated shortage, an hospital-based 3D printing platform was implemented in our institution for the production of swabs for nasopharyngeal and oropharyngeal sampling based on the freely available open-sourced design made available to the community by University of South Florida’s Health Radiology and Northwell Health System teams as replacement for locally used commercial swabs. Validation of our 3D printed swabs was performed by a head-to-head diagnostic accuracy study of the 3D printed “Northwell model” with the cobas PCR Media swabs sample kit. We observed an excellent concordance (total agreement 96.8%, Kappa 0.936) in results obtained with the 3D printed and flocked swabs indicating that the in-house 3D printed swab can be used reliably in a context of shortage of flocked swabs. To our knowledge, this is the first study to report on autonomous hospital-based production and clinical validation of 3D printed swabs.Competing Interest StatementSGL has received funding from Roche Diagnosis unrelated to the present study to test PCR Medium stability. FC received grants paid to the organization for research projects unrelated to the present study from Roche Diagnostics and Merck Sharp and Dome honorariums for presentations from Merck Sharp and Dome and Roche diagnostics, and has participated in an expert vaccine group by Merck Sharp and DomeFunding StatementThis study was funded by the TELUS Friendly Future Foundation/Fondation TELUS pour un futur meilleur and the Fondation du Centre Hospitalier de Universite de Montreal. The funders had no role in the study design, data collection and interpretation, or the decision to submit the work for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study received ethical approval from the Comite ethique de la Recherche of the Centre de Recherche du Centre Hospitalier de Universite de Montreal (CHUM, 2021-9015 /20.079). All participants were provided written informed consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data described in this manuscript will be provided upon reasonable request.